Brett Breshears, DO
Ophthalmology · Indianapolis, INNPI 1467018945
Payments from drug & device makers
Across 43 payments — averaging $76.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- Glaukos Corporation$748
- NEW World Medical,inc.$431
- Amgen$244
- AbbVie$185
- Dompe US, Inc.$120
- plus $278 from 5 others
What the payments were for
- Food & beverage$3,303100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 16 | $1,296 |
| Glaukos Corporation | 9 | $748 |
| NEW World Medical,inc. | 5 | $431 |
| Amgen(2 entities) | 2 | $244 |
| AbbVie | 2 | $185 |
| Dompe US, Inc. | 1 | $120 |
| Sight Sciences, Inc. | 4 | $90 |
| Genentech, Inc. | 1 | $88 |
| Alimera Sciences, Inc. | 1 | $46 |
| Apellis Pharmaceuticals, Inc. | 1 | $30 |
| Aerie Pharmaceuticals, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$543
- TEPEZZA$244
- Kahook Dual Blade$207
- Clearpath$207
- Ahmed Glaucoma Valve$207
- Streamline$207
- iStent inject W$163
- Clareon$148
- iDoseTR$130
- Oxervate$120
- NGENUITY$118
- Rocklatan$111
- SIMBRINZA$111
- Rhopressa$111
- iStent Trabecular Micro-Bypass System Model iS3$108
- Centurion$107
How this compares
$3,303 in reported general payments places this provider in the 70th percentile of 266 ophthalmology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 88 | $3,352 |
| Brimonidine Tartrate | 37 | $1,021 |
| Dorzolamide Hcl | 47 | $721 |
| Latanoprost | 81 | $705 |
| Ketorolac Tromethamine | 18 | $280 |
| Timolol Maleate | 50 | $266 |
| Ofloxacin | 17 | $179 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 12 | $164 |
| Ciprofloxacin Hcl | 16 | $76 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Indianapolis
- Kevin WaltzIndianapolis$765K
- Francis PriceIndianapolis$500K
- Blair BoehmerIndianapolis$128K
- John LindIndianapolis$125K
- William WhitsonIndianapolis$98K
- Janet HummerIndianapolis$96K
- Shaohui LiuIndianapolis$92K
- Darrell WudunnIndianapolis$67K
- Robert DeitchIndianapolis$27K
- Michael OrrIndianapolis$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.